通过特定位点的PEG- 2调节性T细胞激活可缓解自身免疫性炎症
Masahiro Ikeda1, Shinpei Yamaguchi2, Shigeki Takaoka1
1Tokyo Research Park, Kyowa Kirin Co., Ltd., 3-6-6, Asahi-machi, Machida-shi, Tokyo, Japan.
Journal of translational autoimmunity
|September 2, 2025
概括
一种新型的互白素-2 (IL-2) 变体,I129-W80,选择性地向调节性T细胞 (Tregs),以恢复自身免疫性疾病中的免疫平衡. 这种工程蛋白比现有的治疗方法有更长的半衰期和效果.
科学领域:
- 免疫学
- 生物技术
- 药理学
背景情况:
- 免疫失调和调节性T细胞 (Treg) 功能障碍是自身免疫和炎症性疾病的核心原因.
- 低剂量互白素-2 (IL-2) 治疗可以改善Treg功能,但其半衰期短且异于目标效应.
- 现有的IL-2变体,如Fc融合蛋白,可能无法完全克服诱受体抑制等限制.
研究的目的:
- 开发和描述一种新的IL-2变体,I129-W80,具有增强的Treg选择性和药物动力学特性.
- 评估I129-W80在纠正免疫失衡和治疗自身免疫疾病模型中的 in vitro 和 in vivo 疗效.
- 将I129-W80与现有的IL-2变种 (包括AMG-592) 的性能进行比较.
主要方法:
- 使用特定位点的PEGylation生成具有IL- 2Rα偏差结合特征的I129- W80IL-2变体.
- 在体外测试中评估了选择性Treg激活和克服可溶性IL- 2Rα抑制的能力.
- 在非人类灵长类动物和炎症和自身免疫性疾病的动物模型中的体内研究评估了药理动力学,疗效和组织分布.
主要成果:
- 在实验室中,I129- W80可选择性激活Tregs并克服可溶性IL- 2Rα的抑制.
- 在体内,I129- W80的半衰期延长,Treg放大持续,与相似剂量的AMG-592相比,效果更好.
- 在多种疾病模型中,I129- W80改善了炎症反应,并减少了炎症组织的分布.
结论:
- PEGylated IL-2 变体 I129- W80 具有独特的特性,提供了更好的特异性向和治疗潜力.
- I129-W80有效地纠正由Treg功能障碍引起的免疫失衡,显示为治疗自身免疫性疾病的前景.
- 这种新型代表了与目前基于IL-2的免疫介导疾病治疗方法的显著进步.
相关概念视频
01:24T Cell Types and Functions
1.4K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.4K
01:27Tumor Immunotherapy
659
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
659